Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.56 USD
1.13 B USD
2.35 B USD
379.02 M
About Royalty Pharma plc
Sector
CEO
Pablo Gerardo Legorreta
Headquarters
New York
Website
Founded
2020
ISIN
GB00BMVP7Y09
FIGI
BBG00V1L5YZ5
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of RPRX is 26.22 USD — it has increased by 0.81% in the past 24 hours. Watch Royalty Pharma plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Royalty Pharma plc stocks are traded under the ticker RPRX.
RPRX stock has fallen by −0.91% compared to the previous week, the month change is a −7.50% fall, over the last year Royalty Pharma plc has showed a −2.56% decrease.
We've gathered analysts' opinions on Royalty Pharma plc future price: according to them, RPRX price has a max estimate of 51.00 USD and a min estimate of 39.00 USD. Watch RPRX chart and read a more detailed Royalty Pharma plc stock forecast: see what analysts think of Royalty Pharma plc and suggest that you do with its stocks.
RPRX reached its all-time high on Jun 18, 2020 with the price of 56.50 USD, and its all-time low was 25.10 USD and was reached on Nov 15, 2024. View more price dynamics on RPRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RPRX stock is 1.90% volatile and has beta coefficient of 0.01. Track Royalty Pharma plc stock price on the chart and check out the list of the most volatile stocks — is Royalty Pharma plc there?
Today Royalty Pharma plc has the market capitalization of 11.56 B, it has increased by 62.28% over the last week.
Yes, you can track Royalty Pharma plc financials in yearly and quarterly reports right on TradingView.
Royalty Pharma plc is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
RPRX earnings for the last quarter are 0.92 USD per share, whereas the estimation was 0.93 USD resulting in a −1.09% surprise. The estimated earnings for the next quarter are 1.04 USD per share. See more details about Royalty Pharma plc earnings.
Royalty Pharma plc revenue for the last quarter amounts to 735.00 M USD, despite the estimated figure of 696.92 M USD. In the next quarter, revenue is expected to reach 599.37 M USD.
RPRX net income for the last quarter is 543.99 M USD, while the quarter before that showed 102.00 M USD of net income which accounts for 433.30% change. Track more Royalty Pharma plc financial stats to get the full picture.
Yes, RPRX dividends are paid quarterly. The last dividend per share was 0.21 USD. As of today, Dividend Yield (TTM)% is 3.19%. Tracking Royalty Pharma plc dividends might help you take more informed decisions.
Royalty Pharma plc dividend yield was 2.85% in 2023, and payout ratio reached 31.57%. The year before the numbers were 1.92% and 777.10% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 21, 2024, the company has 89.00 employees. See our rating of the largest employees — is Royalty Pharma plc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Royalty Pharma plc EBITDA is 1.54 B USD, and current EBITDA margin is 63.37%. See more stats in Royalty Pharma plc financial statements.
Like other stocks, RPRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Royalty Pharma plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Royalty Pharma plc technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Royalty Pharma plc stock shows the sell signal. See more of Royalty Pharma plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.